Official UK visa sponsor profile for Thrombosis Research Institute in London, including current register status, route details, and public company data.
Thrombosis Research Institute (TRI) is a privately-limited guaranteed NSc (Non-Specified Company) established in 1987, operating from its address at Emmanuel Kaye Building, Chelsea, SW3 6LR, UK. TRI specializes in research and experimental development focused on biotechnology applications within the thrombosis and cardiovascular health sectors. The institute’s core mission is to accelerate the advancement of knowledge and innovation in these critical areas. TRI’s activities encompass a broad spectrum of research, including the investigation of novel therapeutic targets and the development of innovative diagnostic tools. Specifically, the institute concentrates on understanding and mitigating the risks associated with blood clots and cardiovascular diseases. TRI’s services are primarily geared towards preclinical research, utilizing advanced methodologies and sophisticated laboratory techniques. The institute’s international presence is currently limited, primarily operating within the UK. TRI employs a team of highly skilled researchers and technicians, demonstrating a commitment to continuous innovation and strategic investment in research capabilities. The company’s size is estimated to be relatively small, reflecting its dedicated focus on specialized research. TRI’s SIC codes include -72110, indicating its primary focus on biotechnology research and development.
Official UK visa sponsor profile for Thrombosis Research Institute in London, including current register status, route details, and public company data.
Thrombosis Research Institute (TRI) is a privately-limited guaranteed NSc (Non-Specified Company) established in 1987, operating from its address at Emmanuel Kaye Building, Chelsea, SW3 6LR, UK. TRI specializes in research and experimental development focused on biotechnology applications within the thrombosis and cardiovascular health sectors. The institute’s core mission is to accelerate the advancement of knowledge and innovation in these critical areas. TRI’s activities encompass a broad spectrum of research, including the investigation of novel therapeutic targets and the development of innovative diagnostic tools. Specifically, the institute concentrates on understanding and mitigating the risks associated with blood clots and cardiovascular diseases. TRI’s services are primarily geared towards preclinical research, utilizing advanced methodologies and sophisticated laboratory techniques. The institute’s international presence is currently limited, primarily operating within the UK. TRI employs a team of highly skilled researchers and technicians, demonstrating a commitment to continuous innovation and strategic investment in research capabilities. The company’s size is estimated to be relatively small, reflecting its dedicated focus on specialized research. TRI’s SIC codes include -72110, indicating its primary focus on biotechnology research and development.
Yes, Thrombosis Research Institute is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
Thrombosis Research Institute is classified under: Research and experimental development on biotechnology.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.
Yes, Thrombosis Research Institute is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
Thrombosis Research Institute is classified under: Research and experimental development on biotechnology.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.